Bahrami, E., et al. (2023). Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo. Mol Cancer 22, 107. 10.1186/s12943-023-01803-0.

Dill, V., et al. (2023). Elevated RIPK3 correlates with disease burden in myelofibrosis. Blood Adv 7, 1219- 1224. 10.1182/bloodadvances.2021006838

Issa, G.C., et al. (2023). The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 615, 920-924. 10.1038/s41586-023-05812-3.

Jaeger, A., et al. (2023). Activated granulocytes and inflammatory cytokine signaling drive T-cell lymphoma progression and disease symptoms. Blood 141, 2824-2840. 10.1182/blood.2022015653.

Klever, M.K., et al. (2023). AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology. Blood Adv. 10.1182/bloodadvances.2023010887.

Lichtner, G., et al. (2023). Interoperable, Domain-Specific Extensions for the German Corona Consensus (GECCO) COVID-19 Research Data Set Using an Interdisciplinary, Consensus-Based Workflow: Data Set Development Study. JMIR Med Inform 11, e45496. 10.2196/45496.

Naher, A.F., et al. (2023). Secondary data for global health digitalisation. Lancet Digit Health 5, e93-e101. 10.1016/S2589-7500(22)00195-9.

Perner, F., et al. (2023). MEN1 mutations mediate clinical resistance to menin inhibition. Nature 615, 913-919. 10.1038/s41586-023-05755-9.

Stegelmann, F. et al. Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN). Leukemia 37, 924-928 (2023). https://doi.org:10.1038/s41375-023-01837-9

Stellmach, C., et al. (2023). Creation of a structured molecular genomics report for Germany as a local adaption of HL7’s Genomic Reporting Implementation Guide. J Am Med Inform Assoc 30, 1179-1189. 10.1093/jamia/ocad061.

Aubrey, B.J., et al. (2022). IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia. Nat Cancer 3, 595-613. 10.1038/s43018-022-00366-1.

Cerisoli, F., et al. (2022). Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools. Value Health 25, 1760-1767. 10.1016/j.jval.2022.04.1729

Ernst, P., et al. (2022). Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms. Leukemia 36, 1843-1849. 10.1038/s41375-022-01611-3.

Hernandez-Malmierca, P., et al. (2022). Antigen presentation safeguards the integrity of the hematopoietic stem cell pool. Cell Stem Cell 29, 760-775 e710. 10.1016/j.stem.2022.04.007.

Jacobsen, J.O.B., et al. (2022). The GA4GH Phenopacket schema defines a computable representation of clinical data. Nat Biotechnol 40, 817-820. 10.1038/s41587-022-01357-4.

Jahn, N., et al. (2022). Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial. Leukemia 36, 2218-2227. 10.1038/s41375-022-01650-w

Jayavelu, A.K., et al. (2022). The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 40, 301- 317 e312. 10.1016/j.ccell.2022.02.006.

Krenn, P. W., Montanez, E., Costell, M. & Fässler, R. Integrins, anchors and signal transducers of hematopoietic stem cells during development and in adulthood. Curr Top Dev Biol 149, 203-261 (2022). https://doi.org:10.1016/bs.ctdb.2022.02.009

Olsen, S.N., et al. (2022). MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape. Mol Cell 82, 1140-1155 e1111. 10.1016/j.molcel.2022.02.013.

Rinaldi, E., et al. (2022). Harmonization and standardization of data for a pan-European cohort on SARSCoV-2 pandemic. NPJ Digit Med 5, 75. 10.1038/s41746-022-00620-x

Perner, F., et al. (2022). YBX1 mediates translation of oncogenic transcripts to control cell competition in AML. Leukemia 36, 426-437. 10.1038/s41375-021-01393-0

Schnoeder, T.M., et al. (2022). PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood 139, 1080-1097. 10.1182/blood.2021012778.

Vorisek, C.N., et al. (2022). Fast Healthcare Interoperability Resources (FHIR) for Interoperability in Health Research: Systematic Review. JMIR Med Inform 10, e35724. 10.2196/35724.

Baumeister, J., Chatain, N., Sofias, A. M., Lammers, T. & Koschmieder, S. Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives. Cells 10 (2021). https://doi.org:10.3390/cells10123551

Dolnik, A., et al. (2021). Genome Sequencing in Myeloid Cancers. N Engl J Med 384, e106. 10.1056/NEJMc2106014.

Haider, N., et al. (2021). Signaling defects associated with insulin resistance in nondiabetic and diabetic individuals and modification by sex. J Clin Invest 131. 10.1172/JCI151818.

Heidel, F.H., et al. (2021). The Genomic Landscape of Myeloid Malignancies: Options for Pan-myeloid Therapies? Hemasphere 5, e537. 10.1097/HS9.0000000000000537.

Heikamp, E.B., et al. (2021). The Menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML. Blood. 10.1182/blood.2021012806.

Leimkühler, N. B. et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell 28, 637-652.e638 (2021). https://doi.org:10.1016/j.stem.2020.11.004

Lux, S., et al. (2021). Deregulated expression of circular RNAs in acute myeloid leukemia. Blood Adv 5, 1490-1503. 10.1182/bloodadvances.2020003230.

Schmalbrock, L.K., et al. (2021). Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood 137, 3093-3104. 10.1182/blood.2020007626.

Serramito-Gomez, I., et al. (2021). NEMHESYS-European Perspective on the Implementation of Nextgeneration Sequencing Into Clinical Diagnostics. Hemasphere 5, e541. 10.1097/HS9.0000000000000541.

Olschok, K. et al. CALR frameshift mutations in MPN patient-derived iPSCs accelerate maturation of megakaryocytes. Stem Cell Reports 16, 2768-2783 (2021). https://doi.org:10.1016/j.stemcr.2021.09.019

Zeiser, R., et al. (2021). Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med 385, 228-238. 10.1056/NEJMoa2033122.

Batista, T.M., et al. (2020). A Cell-Autonomous Signature of Dysregulated Protein Phosphorylation Underlies Muscle Insulin Resistance in Type 2 Diabetes. Cell Metab 32, 844-859 e845. 10.1016/j.cmet.2020.08.007.

Hamarsheh, S., et al. (2020). Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun 11, 1659. 10.1038/s41467-020-15497-1.

Jahn, N., et al. (2020). Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Adv 4, 6342-6352. 10.1182/bloodadvances.2020002673.

Jayavelu, A.K., et al. (2020). Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 588, 157-163. 10.1038/s41586-020-2968-3.

Kapp-Schwoerer, S., et al. (2020). Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood 136, 3041-3050. 10.1182/blood.2020005998.

Krenn, P. W., Koschmieder, S. & Fässler, R. Kindlin-3 loss curbs chronic myeloid leukemia in mice by mobilizing leukemic stem cells from protective bone marrow niches. Proc Natl Acad Sci U S A 117, 24326- 24335 (2020). https://doi.org:10.1073/pnas.2009078117

Lang, K.M., et al. (2020). Core outcome set measurement for future clinical trials in acute myeloid leukemia: the HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting. Trials 21, 437. 10.1186/s13063-020-04384-1.

Perner, F., et al. (2020). Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation. Cells 9. 10.3390/cells9122721.

Radke, T.F., et al. (2020). Evaluation of current genetic testing reports in German-speaking countries with regard to secondary use and future electronic implementation. Eur J Hum Genet 28, 558-566. 10.1038/s41431-020-0586-z.

Reich, D., et al. (2020). SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. Leukemia 34, 1444-1449. 10.1038/s41375-019-0676-5.

Uckelmann, H.J., et al. (2020). Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science 367, 586-590. 10.1126/science.aax5863.

Uhl, F.M., et al. (2020). Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med 12. 10.1126/scitranslmed.abb8969.

Zeiser, R., et al. (2020). Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med 382, 1800-1810. 10.1056/NEJMoa1917635.

Cocciardi, S., et al. (2019). Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nat Commun 10, 2031. 10.1038/s41467-019-09745-2.

Czech, J. et al. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia 33, 995-1010 (2019). https://doi.org:10.1038/s41375-018-0295-6

Jutzi, J.S., et al. (2019). Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations. Blood 133, 1766-1777. 10.1182/blood-2018-09-875047.

Krivtsov, A.V., et al. (2019). A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia. Cancer Cell 36, 660-673 e611. 10.1016/j.ccell.2019.11.001.

Perner, F., et al. (2019). Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. Cells 8. 10.3390/cells8080854.

Schubert, C. et al. Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABLpositive cells to interferon alpha. J Hematol Oncol 12, 36 (2019). https://doi.org:10.1186/s13045-019-0722-9

Vorbach, S., et al. (2019). Enhanced expression of the sphingosine-1-phosphate-receptor-3 causes acute myelogenous leukemia in mice. Leukemia. 10.1038/s41375-019-0577-7.

Jutzi, J.S., et al. (2018). LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone. Hemasphere 2, e54. 10.1097/HS9.0000000000000054.

Mathew, N.R., et al. (2018). Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24, 282-291. 10.1038/nm.4484.

Prestipino, A., et al. (2018). Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med 10. 10.1126/scitranslmed.aam7729.

Bogeska, R., et al. (2013). Elevated nuclear factor erythroid-2 levels promote epo-independent erythroid maturation and recapitulate the hematopoietic stem cell and common myeloid progenitor expansion observed in polycythemia vera patients. Stem Cells Transl Med 2, 112-117. 10.5966/sctm.2012-0046.

Damm, F., et al. (2014). Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov 4, 1088-1101. 10.1158/2159-8290.CD-14-0104.

Dierks, C. (2010). GDC-0449–targeting the hedgehog signaling pathway. Recent Results Cancer Res 184, 235-238. 10.1007/978-3-642-01222-8_17.

Dierks, C., et al. (2010). The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 70, 6193-6204. 10.1158/0008-5472.CAN-08-3719.

Dierks, C., et al. (2008). Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238-249. 10.1016/j.ccr.2008.08.003.

Dierks, C., et al. (2007). Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 13, 944-951. 10.1038/nm1614.

Fleischman, A.G., et al. (2011). TNFalpha facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood 118, 6392-6398. 10.1182/blood-2011-04-348144.

Grundler, R., et al. (2009). Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 206, 1957-1970. 10.1084/jem.20082074

Heidel, F.H., et al. (2012). Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 10, 412-424. 10.1016/j.stem.2012.02.017.

Hofbauer, S. W. et al. The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. Br J Haematol 172, 815-819 (2016). https://doi.org:10.1111/bjh.13542

Hofbauer, S. W. et al. Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. Blood 123, 2181-2188 (2014). https://doi.org:10.1182/blood-2013-08- 523563

Hockendorf, U., et al. (2016). RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell 30, 75-91. 10.1016/j.ccell.2016.06.002.

Jutzi, J.S., et al. (2015). The Hen or the Egg: Inflammatory Aspects of Murine MPN Models. Mediators Inflamm 2015, 101987. 10.1155/2015/101987

Jutzi, J.S., et al. (2013). MPN patients harbor recurrent truncating mutations in transcription factor NF-E2. J Exp Med 210, 1003-1019. 10.1084/jem.20120521.

Kaufmann, K.B., et al. (2012). A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2. J. Exp. Med. 209, 35-50. 10.1084/jem.20110540.

Klein, C., et al. (2016). Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. J Exp Med 213, 273-290. 10.1084/jem.20150556.

Koschmieder, S., et al. (2016). Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia 30, 1018-1024. 10.1038/leu.2016.12.

Schnoder, T.M., et al. (2017). Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. J Cancer Res Clin Oncol 143, 807-820. 10.1007/s00432-017-2354-1.

Sprissler, C., et al. (2014). Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice. Blood Cancer J 4, e240. 10.1038/bcj.2014.53.

Wehrle, J., et al. (2013). Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms. Haematologica 98, 1073-1080. 10.3324/haematol.2012.071183.

Wilhelm, K., et al. (2010). Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med 16, 1434-1438. 10.1038/nm.2242.